Chlorambucil – rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis

D. Laszlo Division of Hemato-Oncology, European Institute of Oncology, Milan, ItalyCorrespondence[email protected]

C. Rabascio Division of Hemato-Oncology, European Institute of Oncology, Milan, Italy

G. Andreola Division of Hemato-Oncology, European Institute of Oncology, Milan, Italy

G. Pruneri Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy

V. Raia Division of Hemato-Oncology, European Institute of Oncology, Milan, Italy

L. Calabrese Division of Hemato-Oncology, European Institute of Oncology, Milan, Italy

D. Radice Division of Statistical Analysis, European Institute of Oncology, Milan, Italy

L. Saronni Division of Hemato-Oncology, European Institute of Oncology, Milan, Italy

G. Martinelli Division of Hemato-Oncology, European Institute of Oncology, Milan, Italy

show all

References

Gribben J, Neuberg D, Freedman A, Gimmi C D, Pesek K W, Barber M, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449–3457
PubMed Web of Science ®Google Scholar
Cohen Y, Solal-Celigny P, Polliack A. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance. Haemtologica 2003; 88: 811–823
PubMed Web of Science ®Google Scholar
Martinelli G, Laszlo D, Bertolini F, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Haematol 2003; 123: 271–277
PubMed Web of Science ®Google Scholar
The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–3918
PubMed Web of Science ®Google Scholar
Rambaldi A, Carlotti E, Oldani E, et al. Quantitatite PCR of bone marrow BCL2/IgH positive cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin's lymphoma. Blood 2005; 105: 3428–3433
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Chlorambucil – rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Chlorambucil – rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: A clinical and biological analysis

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date